AKRO - Akero Therapeutics (AKRO) SYMMETRY Study Under Fire in Class Action – AKRO Investors with Substantial Losses Encouraged to Contact Hagens Berman by June 25 2024 | Benzinga
SAN FRANCISCO, May 13, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Akero Therapeutics, Inc. (NASDAQ:AKRO) investors who suffered substantial losses to submit their losses now.
Class Period: Sep. 13, 2022 – Oct. 9, 2023
Lead Plaintiff Deadline: June 25, 2024
Visit: www.hbsslaw.com/investor-fraud/AKRO
Contact the Firm Now: AKRO@hbsslaw.com
844-916-0895
Akero Therapeutics, Inc. (AKRO) Class Action:
Akero Therapeutics, a biopharmaceutical company developing treatments for liver disease, is under fire from investors in a securities class action lawsuit. The lawsuit alleges that Akero misled investors about a key clinical trial designed to evaluate their lead drug candidate efruxifermin.
The trial, called SYMMETRY, investigated efruxifermin's effectiveness in treating nonalcoholic steatohepatitis (NASH). However, the lawsuit ...
AKRO) SYMMETRY Study Under Fire in Class Action – AKRO Investors with Substantial Losses Encouraged to Contact Hagens Berman by June 25, 2024>Full story available on Benzinga.com